Please select the option that best describes you:
Would you give KEYNOTE 522 in combination with trastuzumab/pertuzumab neoadjuvantly for multifocal disease?
In the setting of one lesion being TNBC (T1bN1) and the other ER neg/HER2+ (T1cN0) in the same breast